Emergex Vaccines Holding Ltd.

A biotechnology company developing vaccines against viral and bacterial infectious diseases

Emergex, a clinical-stage, privately-held biotechnology company headquartered in Milton Park, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of 100% synthetic T cell Adaptive Vaccines that harness the body’s natural T cell immune response to destroy pathogen-infected cells for protection against some of the world’s most pressing health threats, including viral infectious diseases, such as Dengue Fever, COVID-19, pandemic Influenza, as well as serious intra-cellular bacterial infections.